Cargando…

The Biomarker Potential of miRNAs in Myotonic Dystrophy Type I

MicroRNAs (miRNAs) are mostly known for their gene regulation properties, but they also play an important role in intercellular signaling. This means that they can be found in bodily fluids, giving them excellent biomarker potential. Myotonic Dystrophy type I (DM1) is the most frequent autosomal dom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koehorst, Emma, Ballester-Lopez, Alfonsina, Arechavala-Gomeza, Virginia, Martínez-Piñeiro, Alicia, Nogales-Gadea, Gisela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762003/ https://www.ncbi.nlm.nih.gov/pubmed/33291833 http://dx.doi.org/10.3390/jcm9123939

Ejemplares similares

An Overview of Alternative Splicing Defects Implicated in Myotonic Dystrophy Type I
por: López-Martínez, Andrea, et al.
Publicado: (2020)

Characterization of RAN Translation and Antisense Transcription in Primary Cell Cultures of Patients with Myotonic Dystrophy Type 1
por: Koehorst, Emma, et al.
Publicado: (2021)

Preliminary Findings on CTG Expansion Determination in Different Tissues from Patients with Myotonic Dystrophy Type 1
por: Ballester-Lopez, Alfonsina, et al.
Publicado: (2020)

Three-dimensional imaging in myotonic dystrophy type 1: Linking molecular alterations with disease phenotype
por: Ballester-Lopez, Alfonsina, et al.
Publicado: (2020)

The Need for Establishing a Universal CTG Sizing Method in Myotonic Dystrophy Type 1
por: Ballester-Lopez, Alfonsina, et al.
Publicado: (2020)

Six Serum miRNAs Fail to Validate as Myotonic Dystrophy Type 1 Biomarkers
por: Fernandez-Costa, Juan M., et al.
Publicado: (2016)

Senescence plays a role in myotonic dystrophy type 1
por: García-Puga, Mikel, et al.
Publicado: (2022)

Elevated Muscle-Specific miRNAs in Serum of Myotonic Dystrophy Patients Relate to Muscle Disease Progress
por: Koutsoulidou, Andrie, et al.
Publicado: (2015)

An Integrative Analysis of DNA Methylation Pattern in Myotonic Dystrophy Type 1 Samples Reveals a Distinct DNA Methylation Profile between Tissues and a Novel Muscle-Associated Epigenetic Dysregulation
por: Koehorst, Emma, et al.
Publicado: (2022)

miRNAs as serum biomarkers for Duchenne muscular dystrophy
por: Cacchiarelli, Davide, et al.
Publicado: (2011)

Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1
por: Perfetti, A., et al.
Publicado: (2016)

An Overview of Circular RNAs and Their Implications in Myotonic Dystrophy
por: Czubak, Karol, et al.
Publicado: (2019)

Erratum: Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1
por: Perfetti, A., et al.
Publicado: (2017)

Myotonic dystrophy
por: Patterson, VH
Publicado: (1990)

Derepressing muscleblind expression by miRNA sponges ameliorates myotonic dystrophy-like phenotypes in Drosophila
por: Cerro-Herreros, Estefania, et al.
Publicado: (2016)

Deregulated MicroRNAs in Myotonic Dystrophy Type 2
por: Greco, Simona, et al.
Publicado: (2012)

Dysregulation of Circular RNAs in Myotonic Dystrophy Type 1
por: Voellenkle, Christine, et al.
Publicado: (2019)

Regulatory Potential of Competing Endogenous RNAs in Myotonic Dystrophies
por: Koscianska, Edyta, et al.
Publicado: (2021)

Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies
por: Soblechero‐Martín, Patricia, et al.
Publicado: (2021)

Epigenetics of Myotonic Dystrophies: A Minireview
por: Visconti, Virginia Veronica, et al.
Publicado: (2021)

Cancer and Myotonic Dystrophy
por: D’Ambrosio, Eleonora S., et al.
Publicado: (2023)

Circulating miRNAs are generic and versatile therapeutic monitoring biomarkers in muscular dystrophies
por: Israeli, David, et al.
Publicado: (2016)

Quantitative Methods to Monitor RNA Biomarkers in Myotonic Dystrophy
por: Wojciechowska, Marzena, et al.
Publicado: (2018)

TNNT2 Missplicing in Skeletal Muscle as a Cardiac Biomarker in Myotonic Dystrophy Type 1 but Not in Myotonic Dystrophy Type 2
por: Bosè, Francesca, et al.
Publicado: (2019)

Special Issue “Genetic Advances in Neuromuscular Disorders: From Gene Identification to Gene Therapy”
por: Arechavala-Gomeza, Virginia, et al.
Publicado: (2021)

Exosomal miRNAs as Biomarkers for Prostate Cancer
por: Hessvik, Nina Pettersen, et al.
Publicado: (2013)

Desflurane anaesthesia in myotonic dystrophy
por: Gandhi, Ranju, et al.
Publicado: (2011)

Myotonic Dystrophy: An Anaesthetic Dilemma
por: Gupta, N, et al.
Publicado: (2009)

Cardiac involvement in myotonic dystrophy
por: Khalighi, Koroush, et al.
Publicado: (2015)

Steakhouse Syndrome in Myotonic Dystrophy
por: Ogasawara, Nobuhiko, et al.
Publicado: (2017)

Cutaneous findings in myotonic dystrophy
por: Kong, Ha Eun, et al.
Publicado: (2022)

Researcher's Perceptions on Publishing “Negative” Results and Open Access
por: Echevarría, Lucía, et al.
Publicado: (2021)

Experimental Model Systems Used in the Preclinical Development of Nucleic Acid Therapeutics
por: Zhou, Haiyan, et al.
Publicado: (2023)

MiRNAs, Myostatin, and Muscle MRI Imaging as Biomarkers of Clinical Features in Becker Muscular Dystrophy
por: Marozzo, Roberta, et al.
Publicado: (2020)

Marathoning with myotonic dystrophy type 2 (proximal myotonic myopathy) and leukopenia
por: Finsterer, Josef, et al.
Publicado: (2017)

Splicing modulation therapy in the treatment of genetic diseases
por: Arechavala-Gomeza, Virginia, et al.
Publicado: (2014)

Respiratory failure in myotonic dystrophy 1
Publicado: (2013)

Multidimensional aspects of pain in myotonic dystrophies
por: Peric, Marina, et al.
Publicado: (2015)

Myotonic Dystrophy—A Progeroid Disease?
por: Meinke, Peter, et al.
Publicado: (2018)

Hyperostosis Frontalis Interna in Myotonic Dystrophy
por: Suzuki, Keisuke, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_38llshdp9buschtfrk4jqi4h65